Abivax (AAVXF) Non-Current Deferred Tax Liability (2025 - 2026)
Abivax (AAVXF) posted Non-Current Deferred Tax Liability of $7.1 million for Q1 2026, up 4.5% on a QoQ basis from $6.8 million in Q4 2025.
Powered by 
Analysis
Abivax (AAVXF) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Abivax has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $7.1 million in Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.8 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was $7.1 million for Q1 2026 at Abivax, up from $6.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $7.1 million in Q1 2026, with the low at $6.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - |